CRO specialized in drug discovery, R&D, preclinical and clinical services
 

Cell Line–Based Oncology Services

Oncology Cell Line Assays Promotion

CliniSciences provides robust, reproducible oncology assays built on well-characterized tumor cell lines, enabling rapid screening, potency ranking, combination testing, and mechanism-of-action support across multiple cancer indications.

Whether you are optimizing a lead series, benchmarking against standard-of-care, or preparing a data package for partnering, our cell line platform delivers high-throughput, decision-ready results.

Why Cell Lines with CliniSciences

Cell line assays remain the fastest and most cost-efficient way to:

  • Prioritize compounds and formulations early
  • Generate dose–response curves across tumor types
  • Explore combination strategies and synergy
  • Produce clean datasets for internal milestones or external partnering

Quality commitments

  • Cell line authentication (STR profiling available on request)
  • Mycoplasma testing (routine)
  • Standardized SOPs and reporting formats
  • Full traceability of culture conditions, passages, and assay parameters

Service Modules

1) Oncology Cell Line Panel Screening

Purpose: Rapid activity profiling across a curated panel relevant to your indication.

Options

  • Single indication panels (e.g., breast, colorectal, ovarian, lung, glioblastoma, …)
  • Multi-indication panels for broad activity and repositioning signals
  • Custom panel built around your target biology or mutation context (where available)

Deliverables

  • Ranked efficacy across the panel
  • Dose–response curves and potency metrics (IC50/EC50 as applicable)
  • Summary tables for go/no-go decisions
Oncology cell line panel screening results example

2) Cytotoxicity, Viability & Proliferation Assays (2D)

Readouts available

  • Luminescence viability
  • MTT
  • BrdU incorporation
  • Ki-67 proliferation
  • Live/Dead imaging (Calcein AM / Ethidium homodimer)

Use cases

  • Lead optimization
  • Benchmarking vs competitors / SOC
  • Schedule dependence (time-course)
Cancer cell lines in 2D culture viability assay

3) Combination & Synergy Testing

Purpose: Identify the best combination partners and dosing ratios.

We offer

  • Standard-of-care + your asset
  • Asset + asset (dual mechanisms)
  • Matrix-based synergy studies (Bliss / Loewe / HSA approaches on request)
  • Rank-ordered combination performance across multiple lines

Deliverables

  • Synergy maps and heat tables
  • Combination ranking and recommended dose ratios
  • Clear decision summary for next steps
Combination synergy testing heatmap or matrix

4) 3D Tumor Models from Cell Lines

Add physiological relevance while keeping speed and throughput.

Capabilities

  • Spheroid formation and treatment response
  • 3D viability and growth inhibition readouts
  • 2D vs 3D response comparison

Use cases

  • Better differentiation of similar compounds
  • Stronger translational narrative before patient-derived studies
3D tumor spheroid model under treatment

5) Immuno-Oncology Cell-Based Assays

For immuno-oncology assets, we can build functional co-culture systems.

Options (project-dependent)

  • Tumor–immune co-cultures
  • Immune-mediated tumor killing readouts
  • Flow cytometry immune activation phenotyping
  • Cytokine release readouts (custom)
Immuno-oncology co-culture assay visualization

6) Mechanism-of-Action Support (Add-on)

Go beyond viability to understand how your compound works.

Apoptosis & cell death

  • TUNEL
  • Soluble nucleosome ELISA
  • Cell death kinetics (custom timepoints)

Protein & signaling

  • Western blot / SDS-PAGE
  • Flow cytometry phenotyping
  • Immunocytochemistry
  • Pathway modulation and target engagement (custom markers)

Molecular biology

  • RNA extraction, RT-PCR / qPCR
  • Fragment analysis
  • Cloning/sequencing (research use, as needed)
Mechanism of action pathway analysis example

What You Receive

Every project includes a decision-oriented report:

  • Study design summary and acceptance criteria
  • Methods section with assay conditions and QC checks
  • Dose–response plots and calculated potency metrics
  • Statistical summaries and raw data files
  • Clear interpretation and next-step recommendations

Let’s Build Your Assay Plan

Tell us your:

  • Indication and target / modality (small molecule, antibody, ADC, bispecific, peptide/protein)
  • Preferred comparators (SOC or competitor compounds)
  • Decision point (lead selection, combination strategy, partnering package)

Contact us at tech@clinisciences.com

Get in Touch